Skip to main content
Erschienen in: PharmacoEconomics 12/2004

01.08.2004 | Leading Article

Incorporation of Statistical Uncertainty in Health Economic Modelling Studies Using Second-Order Monte Carlo Simulations

verfasst von: Mark J. C. Nuijten

Erschienen in: PharmacoEconomics | Ausgabe 12/2004

Einloggen, um Zugang zu erhalten

Abstract

Health economic modelling studies are of interest to many parties with different responsibilities and diverging interests. Therefore, it is obvious that recognising the relevance of statistical uncertainty and dealing with it appropriately are required to obtain unbiased results from health economic modelling studies, especially when those data are being used for reimbursement decisions.
In this manuscript we explore the relevance of the incorporation of statistical uncertainty in a health economic model and identify various types of statistical uncertainty. The concepts were applied to a hypothetical Markov model for a hypothetical antiparkinsonian (AP) product. The method was based on the incorporation of probability distributions in the input variables using a second-order Monte Carlo simulation and the definition of minimum relevant differences for clinical and economic input variables and outcomes.
Our paper shows that the outcomes of a health economic model might be severely biased when statistical uncertainty is not taken into account, which justifies the need for the incorporation of statistical uncertainty in a health economic model.
Literatur
1.
Zurück zum Zitat Nuijten MJC, Berto P, Berdeaux G, et al. Trends in decisionmaking process for pharmaceuticals in Western European countries: a focus on emerging hurdles for obtaining reimbursement and a price. HEPAC 2 2001; 4: 162–9CrossRef Nuijten MJC, Berto P, Berdeaux G, et al. Trends in decisionmaking process for pharmaceuticals in Western European countries: a focus on emerging hurdles for obtaining reimbursement and a price. HEPAC 2 2001; 4: 162–9CrossRef
2.
3.
Zurück zum Zitat Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomised controlled trials. Med Care 1992; 30 (3): 231–43PubMedCrossRef Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomised controlled trials. Med Care 1992; 30 (3): 231–43PubMedCrossRef
4.
Zurück zum Zitat Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991; 7 (4): 561–73PubMedCrossRef Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991; 7 (4): 561–73PubMedCrossRef
5.
Zurück zum Zitat Drummond MF, Ludbrook A, Lowson K, et al. Studies in economic appraisal in health care. Oxford, Oxford University Press 1986; 2 Drummond MF, Ludbrook A, Lowson K, et al. Studies in economic appraisal in health care. Oxford, Oxford University Press 1986; 2
6.
Zurück zum Zitat Clemens K, Townsend R, Luscombe F, et al. Methodological and conduct principles for pharmacoeconomic research. Pharmacceconomics 1995; 8 (2): 169–74CrossRef Clemens K, Townsend R, Luscombe F, et al. Methodological and conduct principles for pharmacoeconomic research. Pharmacceconomics 1995; 8 (2): 169–74CrossRef
7.
Zurück zum Zitat Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275–83PubMedCrossRef Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275–83PubMedCrossRef
8.
Zurück zum Zitat Jefferson T, Demichelli V. Are guidelines for peer-reviewing economic evaluation necessary? A survey of current editorial practice. Health Econ 1995; 4: 383–8PubMedCrossRef Jefferson T, Demichelli V. Are guidelines for peer-reviewing economic evaluation necessary? A survey of current editorial practice. Health Econ 1995; 4: 383–8PubMedCrossRef
9.
Zurück zum Zitat Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997 May-Jun; 6 (3): 217–27 Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997 May-Jun; 6 (3): 217–27
10.
Zurück zum Zitat Nuijten MJC. Measuring sensitivity in pharmacoeconomic studies: refining point sensitivity and range sensitivity by incorporating probability distributions. Pharmacceconomics 1999; 16 (1),33–41CrossRef Nuijten MJC. Measuring sensitivity in pharmacoeconomic studies: refining point sensitivity and range sensitivity by incorporating probability distributions. Pharmacceconomics 1999; 16 (1),33–41CrossRef
11.
Zurück zum Zitat Nuijten MJC. Bridging decision analytic modelling with a cross-sectional approach: application to Parkinson’s disease. Pharmacceconomics 2000 Mar; 17 (3): 227–36CrossRef Nuijten MJC. Bridging decision analytic modelling with a cross-sectional approach: application to Parkinson’s disease. Pharmacceconomics 2000 Mar; 17 (3): 227–36CrossRef
12.
Zurück zum Zitat Nuijten MJ, van Iperen P, Palmer C, et al. Cost-effectiveness analysis of entacapone in Parkinson’s disease: a Markov process analysis. Value Health 2001 Jul-Aug; 4 (4): 316–28 Nuijten MJ, van Iperen P, Palmer C, et al. Cost-effectiveness analysis of entacapone in Parkinson’s disease: a Markov process analysis. Value Health 2001 Jul-Aug; 4 (4): 316–28
13.
Zurück zum Zitat Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985; 5 (2): 157–77PubMedCrossRef Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985; 5 (2): 157–77PubMedCrossRef
14.
Zurück zum Zitat Parmigiani G. Measuring uncertainty in complex decision analysis models. Stat Methods Med Res 2002 Dec; 11 (6): 513–37PubMedCrossRef Parmigiani G. Measuring uncertainty in complex decision analysis models. Stat Methods Med Res 2002 Dec; 11 (6): 513–37PubMedCrossRef
15.
Zurück zum Zitat Cooper NJ, Sutton AJ, Abrams KR. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section. Stat Methods Med Res 2002 Dec; 11 (6): 491–512PubMedCrossRef Cooper NJ, Sutton AJ, Abrams KR. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section. Stat Methods Med Res 2002 Dec; 11 (6): 491–512PubMedCrossRef
Metadaten
Titel
Incorporation of Statistical Uncertainty in Health Economic Modelling Studies Using Second-Order Monte Carlo Simulations
verfasst von
Mark J. C. Nuijten
Publikationsdatum
01.08.2004
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 12/2004
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200422120-00001